Smith & Nephew and Johnson & Johnson (J&J) came close to combining their orthopaedics businesses in a deal valued at up to $22 billion, but the talks collapsed late in the process, according to the Financial Times. The two companies had reportedly agreed on the broad structure and main financial terms, only to hit a hard stop on a basic question: who would run the merged operation.
Smith & Nephew reportedly wanted its current chief executive, Deepak Nath, to stay in charge, while J&J pushed for Smith & Nephew's former CEO, Namal Nawana. That kind of stalemate matters because it suggests price wasn't the real obstacle. When leadership and decision-making rights aren't settled, the bigger risk is integration: who can cut costs, set strategy, and force through changes fast enough to justify the premium being paid.
Why control matters in a deal like this
In any large merger, the question of who runs the combined company is often more contentious than the price. That's especially true when the two businesses are very different in size. Here, the unit being discussed—J&J's hip-and-knee replacement business—was valued well above Smith & Nephew's own market value. That mismatch likely made control even more sensitive, because the smaller company would effectively be absorbing a much larger operation.
For investors, this is a reminder that deal risk isn't just about numbers. Even when the financials line up, governance and management can sink a transaction. When leadership control is unresolved, the risk is that promised efficiencies—like cost savings or faster decision-making—never materialise. Buyers often respond by demanding stronger control rights, such as board seats or vetoes on key decisions, or by asking for a lower price to compensate for that uncertainty.
What this means for J&J's DePuy Synthes spin-off
The timing is awkward for J&J. The company has said it plans to separate its orthopaedics operations into a standalone company called DePuy Synthes in October 2025. The unit has reportedly sought a valuation of around $20 billion, and it has drawn interest from private equity firms. A $22 billion deal collapsing over control puts pressure on that target.
Large carve-outs often fail on “who's in charge,” not on spreadsheets. If buyers think governance is unclear, they tend to respond in two ways: demand stronger control rights or ask for a lower price. That's the immediate read-through for J&J's planned separation. A $20 billion-plus price tag is easier to justify when the buyer can quickly reshape the business. If leadership control is the sticking point, deal timelines can stretch and valuation multiples can cap out until the structure clearly answers how the combined company would be run.
For Smith & Nephew, the failed deal leaves the company to continue on its own. The company has been under pressure to improve performance, and a large transaction could have provided a strategic shift. But with the deal off the table, investors will be watching whether Smith & Nephew can deliver growth on its own.
What it means for everyday investors
For ordinary investors, this story is a useful lesson in how deal risk works. When a merger or acquisition falls apart, it's often not about the headline price but about the details of who controls the combined entity. That can affect the value of both companies' shares in the short term.
For J&J shareholders, the failed deal doesn't change the company's core business, but it does raise questions about the planned spin-off. If the market expected a sale to private equity or a strategic buyer, the collapse could mean the spin-off proceeds with a lower valuation. For Smith & Nephew shareholders, the news removes a potential upside from a deal, but it also removes the uncertainty of a complex integration.
As always, it's important to remember that these are corporate events, not personal recommendations. Investors should focus on the fundamentals of the companies they own, and watch for any further announcements about the DePuy Synthes separation.
